FDA-cleared profile

Customize

3D-Side SA · CT/CTA · FDA-cleared (510(k))

Customize supports adult total ankle arthroplasty planning with CT segmentation, 3D models, implant positioning and sizing, plan review, and X-ray-informed planning.

Clinical role
Collaborative review and modification of CT-derived 3D ankle models and implant plans before physician approval.
Images and patients
CT/CTA · Foot/Ankle
Key limitation
Not for diagnosis, spine surgery, or implant, instrument, or patient-specific-device design. Machine-learning segmentation is an initialization that requires engineer supervision and manual editing, followed by physician review.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyCT/CTA · Foot/Ankle
  • Workflow roleCollaborative review and modification of CT-derived 3D ankle models and implant plans before physician approval.
  • Required inputMultislice DICOM CT, CT-derived CAD models, implant-library models, and X-ray information.
  • Output and human actionPhysician-approved 3D treatment plan stored on the server and optionally exported for downstream patient-specific-device processing.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Customize supports adult total ankle arthroplasty planning with CT segmentation, 3D models, implant positioning and sizing, plan review, and X-ray-informed planning.
  • Exact FDA submission
  • Checked 2026-09-03
Workflow role
Collaborative review and modification of CT-derived 3D ankle models and implant plans before physician approval.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Multislice DICOM CT, CT-derived CAD models, implant-library models, and X-ray information.
  • Exact FDA submission
  • Checked 2026-09-03
Output and clinician action
Physician-approved 3D treatment plan stored on the server and optionally exported for downstream patient-specific-device processing.
  • Exact FDA submission
  • Checked 2026-09-03
Care setting
Preoperative orthopaedic planning workflows for adult ankle arthroplasty.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Experienced physicians and supporting 3D-Side engineers involved in ankle arthroplasty planning.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
Not for diagnosis, spine surgery, or implant, instrument, or patient-specific-device design. Machine-learning segmentation is an initialization that requires engineer supervision and manual editing, followed by physician review.
  • Exact FDA submission
  • Checked 2026-09-03
Evidence summary
K221432 reports software verification, segmentation validation, repeatability and reproducibility testing, and 3D tibia and talus model-accuracy testing. The nonadaptive ankle model was trained on 126 CT scans, 70% cadaveric and 30% surgery-eligible cases; numerical endpoint results were not disclosed.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K221432 reports software verification, segmentation validation, repeatability and reproducibility testing, and 3D tibia and talus model-accuracy testing. The nonadaptive ankle model was trained on 126 CT scans, 70% cadaveric and 30% surgery-eligible cases; numerical endpoint results were not disclosed.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Ankle segmentation training images

126 CT scans

  • EndpointMachine-learning initialization for ankle segmentation
  • PopulationCustomize
  • Tested versionCustomize for ankle arthroplasty cleared in K221432

K221432 FDA performance package for Customize

  • DesignManufacturer nonclinical segmentation, repeatability, reproducibility, and 3D-model accuracy testing
  • Population126 ankle CT scans with an average age of 62 years, 32% female and 68% male
  • Scopeexact submission
  • Tested versionCustomize for ankle arthroplasty cleared in K221432
  • Samplen=126
  • IndependenceSponsor or vendor study

K221432

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K221432 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Multislice DICOM CT, CT-derived CAD models, implant-library models, and X-ray information.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-03 · K221432 FDA decision source

  2. Routing

    Source context, not route validation: DICOM CT and X-ray review, server case management, implant library, 3D CAD visualization, and downstream plan export; validate identifiers, model geometry, implant catalog, revision control, approval trace, and surgical availability.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · K221432 FDA decision source · Customize software for personalized medical-device workflows

  3. AI processing

    Source context, not route validation: Server-backed software interface used by 3D-Side personnel and clinicians; current web-platform descriptions are product-family context.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · K221432 FDA decision source · Customize software for personalized medical-device workflows

  4. Returned objects

    Source context, not route validation: Physician-approved 3D treatment plan stored on the server and optionally exported for downstream patient-specific-device processing.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-03 · K221432 FDA decision source

  5. Viewer/worklist/report

    Unresolved route: Physician-approved 3D treatment plan stored on the server and optionally exported for downstream patient-specific-device processing.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-03 · K221432 FDA decision source

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Server-backed software interface used by 3D-Side personnel and clinicians; current web-platform descriptions are product-family context.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
DICOM CT and X-ray review, server case management, implant library, 3D CAD visualization, and downstream plan export; validate identifiers, model geometry, implant catalog, revision control, approval trace, and surgical availability.
  • Exact FDA submission
  • Checked 2026-09-03
Training
Only experienced physicians and supporting 3d-side engineers involved in ankle arthroplasty planning. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Not for diagnosis, spine surgery, or implant, instrument, or patient-specific-device design. Machine-learning segmentation is an initialization that requires engineer supervision and manual editing, followed by physician review.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K221432 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

DICOM CT and X-ray review, server case management, implant library, 3D CAD visualization, and downstream plan export; validate identifiers, model geometry, implant catalog, revision control, approval trace, and surgical availability.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Not for diagnosis, spine surgery, or implant, instrument, or patient-specific-device design. Machine-learning segmentation is an initialization that requires engineer supervision and manual editing, followed by physician review.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Not for diagnosis, spine surgery, or implant, instrument, or patient-specific-device design. Machine-learning segmentation is an initialization that requires engineer supervision and manual editing, followed by physician review.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K221432
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Anatomy
Foot/Ankle
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-08-03
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
24Fields reviewed
8Source classes checked
20Awaiting review PubMed leads
10Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA materials, current product-family sources, selected clinical literature, reimbursement context, and exact-identifier recall candidates were reviewed. Pricing, contracted services, enabled options, final security architecture, and local interoperability remain organization-specific evidence. Automated exact-name discovery found 20 PubMed and 10 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request data-flow, identity, audit, encryption, retention, support-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 2 history items

Source ledger

  1. K221432 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Customize software for personalized medical-device workflows

    3D-Side - Accessed 2026-09-03

    Scope: productFamily, workflowRole, integration, deployment, implementationCapabilities, currentCommercialContext

Research history

  1. K221432 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

Alternatives

Related tools to compare

FDA-cleared K223757

Bonelogic

Disior Ltd

Authorized purpose: Bonelogic 2.2 assists orthopedic healthcare professionals with diagnosis and surgical planning by semi-automatically segmenting bony structures from CT and producing foot and ankle 3D models and measurements for clinician review.

Modality
CT/CTA
Anatomy
Foot/ankle
Decision
2023-12-08
FDA-cleared K240642

SMART Bun-Yo-Matic CT

Disior Ltd

Authorized purpose: Foot and ankle CT analysis for three-dimensional visualization, measurements, and preoperative surgical planning by qualified orthopaedic professionals.

Modality
CT/CTA
Anatomy
Foot/Ankle
Decision
2024-06-20
FDA-cleared K260322

Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)

Mighty Oak Medical

Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.

Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Decision
2026-06-11

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history